GlobeNewswire Inc | Jan 4, 2022 07:00AM EST

January 04, 2022

RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 40th Annual J.P. Morgan Healthcare Conference, which is being conducted as a virtual event, on Monday, January 10, 2022 at 9:45 a.m. ET.

Links to a live audio webcast and replay of the presentation may be accessed in the Investors section of BioCrysts website at http://www.biocryst.com.

About BioCryst Pharmaceuticals BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO (berotralstat) is approved in the United States, the European Union, Japan, the United Kingdom and the United Arab Emirates. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the companys website atwww.biocryst.com.

BCRXW

Investor ContactJohn Bluth+1 919 859 7910jbluth@biocryst.com

Media ContactCatherine Collier Kyroulis+1 917 886 5586ckyroulis@biocryst.com